Showing 6661-6670 of 7019 results for "".
- Lumiere Medical Announces Dinner Serieshttps://practicaldermatology.com/news/20121003-lumiere_medical_announces_dinner_series/2459715/Lumiere Medical's Innovative MD Academy Regional Dinner Series will be held through the month of October. The company invites physician and medical spa owners to learn about the future of anti-aging and body contouring, w
- ISHRS Kicks Off 20th Anniversaryhttps://practicaldermatology.com/news/20121003-ishrs_kicks_off_20th_anniversary/2459716/The International Society of Hair Restoration Surgery kicks off its 20th Anniversary this month. The ISHRS Annual Scientific Meeting is October 17-20 at Atlantis, Paradise Island, the Bahamas. The society is highlighting follicular units in hair res
- Jurlique Offers Holiday Discountshttps://practicaldermatology.com/news/20121002-jurlique_offers_holiday_discounts/2459718/Jurlique released holiday gift sets featuring full-sized product at a 30 to 40 percent savings. The products include: Age-Defying Trio, of Jurlique Purely Age-Defying Serum, Purely Age-Defying Ultra Firm and Lift Cream, and Skin Balancing Face Oi
- Strathspey Crown Hosts Founders Summithttps://practicaldermatology.com/news/20121002-strathspey_crown_hosts_founders_summit/2459717/Strathspey Crown recently hosted its Founders Summit & Retreat at Pelican Hill in Newport Beach, CA. The event gathered approximately 50 of the top physicians from elective healthcare and national leaders from government, healthcare, and f
- Janssen to Develop, Commercialize JAK Inhibitor For Immunological Diseaseshttps://practicaldermatology.com/news/20121002-janssen_to_develop_commercialize_jak_inhibitor_for_immunological_diseases/2459720/Janssen Biotech, Inc. entered into a license agreement with Astellas Pharma Inc. for the worldwide development and commercialization, except in Japan, of ASP015K, an oral, small molecule Janus Kinase (JAK) inhibitor. ASP015K is currently in Phase 2b development as a once-daily oral treatment for mod
- Provectus Pharmaceuticals Publishes Patent Application, PV-10 Resultshttps://practicaldermatology.com/news/20121002-provectus_pharmaceuticals_publishes_patent_application/2459722/Provectus Pharmaceuticals, Inc. announced that a patent application has been published for US and international patents covering the combination of local and systemic immunomodulative therapies for cancer treatment. The patent, entitled "Combination
- Syneron Kicks Off New Campaignhttps://practicaldermatology.com/news/20121002-syneron_kicks_off_new_campaign/2459721/Syneron Medical Ltd. launched a new Break Up. Get Even! campaign for its elure product line. As part of the campaign, five winners will receive a complete elure range of products ($335 value) to “break up” stubborn discoloration and “get even” skin tone. The campaign is run through the company's
- Janssen Launches Online Resource for Healthcare Professionalshttps://practicaldermatology.com/news/20121002-janssen_launches_online_resource_for_healthcare_professionals/2459725/Janssen Scientific Affairs recently launched a new online scientific resource for U.S. healthcare professionals seeking instant access to current information about Janssen products marketed in the U.S. JanssenMD (www.janssenmd.com) is a web-based application is designed for use on desktops, tablets,
- Physician Pessimism, Dissatisfaction Highhttps://practicaldermatology.com/news/20120928-physician_pessimism_dissatisfaction_high/2459726/More than half of American physicians participating in a recent survey say they plan to significantly modify their practice patterns over the next one to three years, new research suggests. They report plans to cut back on patients seen, work part-time, switch to concierge medicine, retire, or take
- Pharma Penalties Total $10.2B Over Two Yearshttps://practicaldermatology.com/news/20120928-pharma_penalties_total_102b_over_two_years/2459727/Pharmaceutical manufacturers have reached a total of 74 settlements, totaling $10.2 billion in financial penalties with federal and state governments between November 2, 2010 and July 18, 2012. That's the conclusion of an updated report from P